"The voice for cancer physicians and their patients in Massachusetts."

  • 05 Jun 2019 11:51 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved the addition of overall survival data in labeling for gilteritinib (Xospata; Astellas) indicated for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. Read full press release. 

  • 28 May 2019 8:02 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved alpelisib (Piqray; Novartis) in combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. Read full press release. 

  • 16 May 2019 8:48 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved Herzuma (trastuzumab-pkrb; Celltrion) as a biosimilar to Herceptin (trastuzumab; Genentech) for patients with HER2-overexpressing breast cancer. Read full press release.

  • 16 May 2019 8:24 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved ado-trastuzumab emtansine (Kadcyla; Genentech) for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. Read full press release. 

  • 16 May 2019 8:14 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved venetoclax (Venclexta; AbbVie and Genentech) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Read full press release. 

  • 13 May 2019 7:36 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved ramucirumab (Cyramza; Lilly) as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP of  ≥ 400 ng/mL and have been previously treated with sorafenib. Read full press release.

  • 22 Apr 2019 1:39 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved pembrolizumab (Keytruda; Merck) plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). Read full press release. 

  • 16 Apr 2019 9:15 AM | Nathan Strunk (Administrator)

    FDA granted accelerated approval to erdafitinib (BALVERSA, Janssen Pharmaceutical Companies) for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Read full press release.

  • 16 Apr 2019 9:12 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck Inc.) for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation or metastatic NSCLC. Patients’ tumors must have no EGFR or ALK genomic aberrations and express PD-L1 (Tumor Proportion Score [TPS] ≥1%) determined by an FDA-approved test. Read full press release.

  • 09 Apr 2019 2:00 PM | Nathan Strunk (Administrator)

    The Food and Drug Administration approved trastuzumab and hyaluronidase-oysk injection, for subcutaneous use (Herceptin Hylecta, Genentech Inc.). Herceptin Hylecta is a combination of trastuzumab, a HER2/neu receptor antagonist, and hyaluronidase, an endoglycosidase, for the treatment of HER2‑overexpressing breast cancer. Read full press release

Upcoming events

  • No upcoming events

Massachusetts Society of Clinical Oncologists (c)

P.O. Box 549154, Waltham, MA, 02454
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software